Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

The therapy for the future

Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

Oppenheimer and Truist Lift Wave Life Sciences Ltd. (WVE) Price Targets After Positive Trial

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...
TipRanks on MSN

Phio advances PH-762 with FDA-backed toxicology study

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, 2025, Phio Pharmaceuticals announced that the U.S. Food and Drug ...